查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年代谢治疗市场预测：按治疗类型、药物类别、配销通路、应用和地区进行的全球分析
市场调查报告书
商品编码
1383471

2030 年代谢治疗市场预测：按治疗类型、药物类别、配销通路、应用和地区进行的全球分析

Metabolism Drugs Market Forecasts to 2030 - Global Analysis By Therapy Type, Drug Class, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球代谢治疗市场规模为 174.5 亿美元，预计预测期内年复合成长率为 8.4%，到 2030 年将达到 308.5 亿美元。

代谢药物是一种旨在影响或调节体内代谢过程的药物。它也被称为代谢调节剂。根据特定药物及其治疗的医疗状况，可以预期会产生不同的效果。代谢调节剂可以改善心血管健康，提高运动成绩，提高能量水平，降低胆固醇水平，并有助于体重管理。

根据世界卫生组织 (WHO) 统计，2016 年约有 6.5 亿人患有肥胖症，预计到 2030 年这一数字将增加四倍以上。

代谢性疾病盛行率上升

随着被诊断出患有糖尿病、肥胖、高血脂症、代谢症候群等代谢性疾病的患者不断增加，需要治疗的患者数量也不断增加。许多代谢紊乱是慢性疾病，需要持续治疗和管理。代谢性疾病种类繁多，治疗所需的药物也多种多样，因此市场形势也多种多样。对治疗此类疾病的药物的需求不断增长，直接支持了代谢治疗市场的成长。

病患人数有限

代谢性疾病，尤其是罕见疾病和孤儿疾病，患者数量往往较少。这意味着与更常见的疾病相比，针对这些疾病的药物的潜在市场是有限的。由于我们的患者人数较少，我们可能无法产生足够的收益来证明代谢疾病治疗的研发、临床试验和行销所需的投资是合理的。由于市场规模较小，製药公司可能在财务上难以收回药物开发的高成本。这可能会导致患者缺乏有竞争力的选择。

联合治疗日益受到关注

药物的组合可以产生协同效应，其中药物的组合效应大于其单独效应的总合。这将改善临床结果并更好地管理代谢疾病。代谢紊乱往往涉及复杂的生理过程，并受到多种因素的影响。联合治疗可以采用更全面的方法来解决这些复杂性，从而实现更有效的疾病管理。因此，其有效性、个体化药物、扩大的治疗选择和最小化的副作用正在推动市场需求。

开发成本高

高开发成本可能会阻碍新陈代谢促进药物市场的发展，因为製药公司会更加规避风险，专注于更安全、既定的药物开发途径，而不是冒险创新代谢促进药物。这是有性别的。此外，为了收回开发成本，製药公司可能需要为改善新陈代谢的药物设定更高的价格。这可能会限制患者的获取，并对医疗保健系统提供负担得起的治疗构成挑战。

COVID-19 的影响

COVID-19 大流行对代谢药物市场产生了不同的影响，取决于特定药物及其潜在疾病。由于封锁、限制以及对前往医疗机构的担忧，有些人推迟了就代谢疾病寻求医疗协助。这导致诊断和治疗的延误，可能影响新陈代谢改善药物市场。另一方面，远端医疗和远端监测技术的引入可能会影响代谢症状的管理方式并影响代谢药物的处方模式。疫情过后市场正在反弹。

预计小分子药物领域在预测期内将是最大的

由于其特异性的性质和优势，小分子药物领域预计将出现良好的成长。小分子药物旨在与特定分子标靶相互作用，例如代谢过程中涉及的酶、受体和信号途径。这可以精确调节代谢途径并治疗糖尿病、高血脂症和肥胖等疾病。小分子药物通常具有较低的製造成本，这使得它们对于患者和医疗保健系统来说具有成本效益。

预计糖尿病管理领域在预测期内将出现最高的年复合成长率

预计糖尿病管理领域在预测期内将出现最高的年复合成长率。代谢药物有助于调节血糖值，在糖尿病管理中发挥重要作用。稳定血糖值，降低高血糖及其相关併发症的风险。改善血糖控制、降低併发症风险、提高生活品质和客製化治疗计划正在推动这一领域的成长。

比最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。在中国、印度、日本和韩国等亚太国家，糖尿病、肥胖和心血管疾病等代谢性疾病的盛行率正在增加。这一趋势是由久坐的生活方式、饮食变化和遗传倾向等因素所驱动的。由于经济成长和中等收入群体的不断壮大，亚太地区许多国家正在增加医疗保健支出。亚太地区各国政府也正在采取措施应对日益严重的代谢紊乱负担。

复合年复合成长率最高的地区：

预计欧洲在预测期内的年复合成长率最高。欧洲是製药业中一个充满活力的部门。欧洲代谢药物市场竞争激烈，跨国製药公司和本土製造商都扮演重要角色。诺和诺德、赛诺菲、Astra Zeneca和礼来等公司在该市场占有重要地位。此外，欧洲还建立了孤儿疾病药物的指定和核准框架，其中还包括某些罕见代谢疾病。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球代谢治疗市场：依治疗方法

  • 基材减少疗法
  • 酵素替代疗法
  • 小分子药物
  • 其他治疗方法

第6章全球代谢治疗市场：依药物类别

  • 降血脂药物
  • 抗糖尿病药
  • 其他药物类别

第7章全球代谢治疗市场：按配销通路

  • 医院药房
  • 零售药房
  • 网路药房

第8章全球代谢治疗市场：依应用分类

  • 糖尿病管理
  • 治疗肥胖症
    • 处方药
    • OTC（商店）补充剂
  • 高血脂症的治疗
    • 他汀类药物
    • 贝特类药物系统
    • PCSK9抑制剂
  • 甲状腺疾病
    • 甲状腺机能低下症
    • 甲状腺功能亢进症
  • 代谢症候群
    • 高血压
    • 血脂异常症
    • 胰岛素抗性
  • 罕见的代谢紊乱
    • 苯酮尿症 (PKU)
    • 高雪氏症
    • 法布瑞氏症
  • 其他用途

第9章全球代谢治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Novartis AG
  • Merck & Co Inc.
  • Sanofi Genzyme
  • Amicus Therapeutics
  • AstraZeneca PLC
  • Horizon Pharma PLC
  • Shire PLC
  • Boehringer Ingelheim
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceuticals
  • GlaxoSmithKline PLC
  • Fuji Yakuhin
  • Mitsubishi Tanabe Pharma
  • Kowa Company
  • LG Life Science
  • Kythera Labs
Product Code: SMRC24319

According to Stratistics MRC, the Global Metabolism Drugs Market is accounted for $17.45 billion in 2023 and is expected to reach $30.85 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Metabolism drugs are medications designed to influence or regulate metabolic processes in the body. They are also known as metabolic modulators. They can have various benefits depending on the specific drug and the medical condition it is intended to treat. Metabolism drugs help the patient to improve cardiovascular health, enhance exercise performance, increase energy levels, reduce cholesterol levels and aids in weight management.

According to the World Health Organization (WHO), about 650 million people suffer from obesity in 2016 and is expected to increase more than four-fold times by 2030.

Market Dynamics:

Driver:

Rising prevalence of metabolic disorders

As the number of individuals diagnosed with metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome continues to rise, there is a larger patient population in need of treatment. Many metabolic disorders are chronic conditions that require ongoing treatment and management. The broad spectrum of metabolic disorders and the diverse range of drugs needed to treat them provide a wide market landscape. This increased demand for medications to manage these conditions directly supports the growth of the metabolism drugs market.

Restraint:

Limited patient populations

Metabolic disorders, especially rare or orphan diseases, often have a small patient population. This means that the potential market for drugs targeting these conditions is limited compared to more prevalent diseases. The small patient population may not generate enough revenue to justify the investment required for research, development, clinical trials, and marketing of a metabolism drug. The smaller market size can make it financially challenging for pharmaceutical companies to recoup the high costs of drug development. This can result in a lack of competitive options for patients.

Opportunity:

Growing focus on combination therapies

Combining drugs can result in synergistic effects, where the combined action of the drugs is greater than the sum of their individual effects. This can lead to improved clinical outcomes, allowing for better management of metabolic disorders. Metabolic disorders often involve complex physiological processes and may be influenced by multiple factors. Combination therapies allow for a more comprehensive approach to address these complexities, leading to more effective disease management. Thereby, their effectiveness, personalized medicines, expanded treatment options and minimization of side effects propels the market demand.

Threat:

High development costs

High development costs can hinder the metabolism drugs market as they can make pharmaceutical companies more risk-averse, leading them to focus on safer, more established drug development pathways rather than taking risks on innovative metabolism drugs. Also, in order to recoup their development costs, pharmaceutical companies may need to set higher prices for metabolism drugs. This can potentially limit access for patients and create challenges for healthcare systems in providing affordable treatments.

COVID-19 Impact

The COVID-19 pandemic has had varying impacts on the metabolism drugs market, depending on the specific drugs and the underlying conditions they treat. Due to lockdowns, restrictions, and concerns about visiting healthcare facilities, some individuals have delayed seeking medical attention for metabolic conditions. This lead to delayed diagnosis and treatment, potentially impacting the metabolism drugs market. On the other hand, the adoption of telemedicine and remote monitoring technologies have influenced how metabolic conditions were managed, potentially affecting prescription patterns for metabolism drugs. The market has been raised back in the post pandemic.

The small molecule drugs segment is expected to be the largest during the forecast period

The small molecule drugs segment is estimated to have a lucrative growth, due to their specific characteristics and benefits. They are designed to interact with specific molecular targets, such as enzymes, receptors, or signalling pathways, involved in metabolic processes. This allows for precise modulation of metabolic pathways, enabling the treatment of disorders like diabetes, hyperlipidemia, and obesity. Small molecule drugs are often less expensive to manufacture and can be more cost-effective for patients and healthcare systems.

The diabetes management segment is expected to have the highest CAGR during the forecast period

The diabetes management segment is anticipated to witness the highest CAGR growth during the forecast period. Metabolism drugs play a crucial role in diabetes management by helping to regulate blood sugar levels. They help to stabilize blood sugar levels, reducing the risk of hyperglycemia (high blood sugar) and its associated complications. It improves blood sugar control, reduces risk of complications, enhances quality of life and also customizes treatment plans which are thereby accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Asia-Pacific countries, including China, India, Japan, and South Korea, are witnessing a rising prevalence of metabolic disorders such as diabetes, obesity, and cardiovascular diseases. This trend is driven by factors like sedentary lifestyles, dietary changes, and genetic predispositions. With economic growth and a rising middle-class population, many countries in the Asia-Pacific region have seen an increase in healthcare expenditure. Also, governments in various Asia-Pacific have been taking measures to address the growing burden of metabolic disorders.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is a dynamic sector within the pharmaceutical industry. The metabolism drugs market in Europe is competitive, with both multinational pharmaceutical companies and local manufacturers playing significant roles. Companies like Novo Nordisk, Sanofi, AstraZeneca, and Eli Lilly have a strong presence in this market. Also, Europe has a well-established framework for orphan drug designation and approval, which includes certain rare metabolic disorders.

Key players in the market

Some of the key players profiled in the Metabolism Drugs Market include: Novartis AG, Merck & Co Inc., Sanofi Genzyme, Amicus Therapeutics, AstraZeneca PLC, Horizon Pharma PLC, Shire PLC, Boehringer Ingelheim, BioMarin Pharmaceutical Inc., Takeda Pharmaceuticals, GlaxoSmithKline PLC, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Kowa Company, LG Life Science, Kythera Labs and Eli Lilly.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Sanofi launched speciality care growth products Beyfortus® and ALTUVIIIO® for the protection of all infants against RSV. Sanofi's profitability has improved as a result of the portfolio restructuring with these products.

In April 2023, Eli Lilly launched the diabetes and weight loss drugs Ozempic and Wegovy. Participants had lost about 21% of their body weight, which was unprecedented. The medications come at a time when obesity is the most prevalent chronic condition, affecting an estimated 650 million adults globally.

Therapy Types Covered:

  • Substrate Reduction Therapy
  • Enzyme Replacement Therapy
  • Small Molecule Drugs
  • Other Therapy Types

Drug Classes Covered:

  • Antihyperlipidemic Drugs
  • Antidiabetic Drugs
  • Other Drug Classes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Diabetes Management
  • Obesity Treatment
  • Hyperlipidemia Management
  • Thyroid Disorders
  • Metabolic Syndrome
  • Rare Metabolic Disorders
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Metabolism Drugs Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Substrate Reduction Therapy
  • 5.3 Enzyme Replacement Therapy
  • 5.4 Small Molecule Drugs
  • 5.5 Other Therapy Types

6 Global Metabolism Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antihyperlipidemic Drugs
  • 6.3 Antidiabetic Drugs
  • 6.4 Other Drug Classes

7 Global Metabolism Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Metabolism Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Diabetes Management
  • 8.3 Obesity Treatment
    • 8.3.1 Prescription Medications
    • 8.3.2 OTC (Over-the-Counter) Supplements
  • 8.4 Hyperlipidemia Management
    • 8.4.1 Statins
    • 8.4.2 Fibrates
    • 8.4.3 PCSK9 Inhibitors
  • 8.5 Thyroid Disorders
    • 8.5.1 Hypothyroidism
    • 8.5.2 Hyperthyroidism
  • 8.6 Metabolic Syndrome
    • 8.6.1 Hypertension
    • 8.6.2 Dyslipidemia
    • 8.6.3 Insulin Resistance
  • 8.8 Rare Metabolic Disorders
    • 8.8.1 Phenylketonuria (PKU)
    • 8.8.2 Gaucher Disease
    • 8.8.3 Fabry Disease
  • 8.8 Other Applications

9 Global Metabolism Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Merck & Co Inc.
  • 11.3 Sanofi Genzyme
  • 11.4 Amicus Therapeutics
  • 11.5 AstraZeneca PLC
  • 11.6 Horizon Pharma PLC
  • 11.7 Shire PLC
  • 11.8 Boehringer Ingelheim
  • 11.9 BioMarin Pharmaceutical Inc.
  • 11.10 Takeda Pharmaceuticals
  • 11.11 GlaxoSmithKline PLC
  • 11.12 Fuji Yakuhin
  • 11.13 Mitsubishi Tanabe Pharma
  • 11.14 Kowa Company
  • 11.15 LG Life Science
  • 11.16 Kythera Labs

List of Tables

  • Table 1 Global Metabolism Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Metabolism Drugs Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 3 Global Metabolism Drugs Market Outlook, By Substrate Reduction Therapy (2021-2030) ($MN)
  • Table 4 Global Metabolism Drugs Market Outlook, By Enzyme Replacement Therapy (2021-2030) ($MN)
  • Table 5 Global Metabolism Drugs Market Outlook, By Small Molecule Drugs (2021-2030) ($MN)
  • Table 6 Global Metabolism Drugs Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 7 Global Metabolism Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 8 Global Metabolism Drugs Market Outlook, By Antihyperlipidemic Drugs (2021-2030) ($MN)
  • Table 9 Global Metabolism Drugs Market Outlook, By Antidiabetic Drugs (2021-2030) ($MN)
  • Table 10 Global Metabolism Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 11 Global Metabolism Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Metabolism Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Metabolism Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Metabolism Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 15 Global Metabolism Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Metabolism Drugs Market Outlook, By Diabetes Management (2021-2030) ($MN)
  • Table 17 Global Metabolism Drugs Market Outlook, By Obesity Treatment (2021-2030) ($MN)
  • Table 18 Global Metabolism Drugs Market Outlook, By Prescription Medications (2021-2030) ($MN)
  • Table 19 Global Metabolism Drugs Market Outlook, By OTC (Over-the-Counter) Supplements (2021-2030) ($MN)
  • Table 20 Global Metabolism Drugs Market Outlook, By Hyperlipidemia Management (2021-2030) ($MN)
  • Table 21 Global Metabolism Drugs Market Outlook, By Statins (2021-2030) ($MN)
  • Table 22 Global Metabolism Drugs Market Outlook, By Fibrates (2021-2030) ($MN)
  • Table 23 Global Metabolism Drugs Market Outlook, By PCSK9 Inhibitors (2021-2030) ($MN)
  • Table 24 Global Metabolism Drugs Market Outlook, By Thyroid Disorders (2021-2030) ($MN)
  • Table 25 Global Metabolism Drugs Market Outlook, By Hypothyroidism (2021-2030) ($MN)
  • Table 26 Global Metabolism Drugs Market Outlook, By Hyperthyroidism (2021-2030) ($MN)
  • Table 27 Global Metabolism Drugs Market Outlook, By Metabolic Syndrome (2021-2030) ($MN)
  • Table 28 Global Metabolism Drugs Market Outlook, By Hypertension (2021-2030) ($MN)
  • Table 29 Global Metabolism Drugs Market Outlook, By Dyslipidemia (2021-2030) ($MN)
  • Table 30 Global Metabolism Drugs Market Outlook, By Insulin Resistance (2021-2030) ($MN)
  • Table 31 Global Metabolism Drugs Market Outlook, By Rare Metabolic Disorders (2021-2030) ($MN)
  • Table 32 Global Metabolism Drugs Market Outlook, By Phenylketonuria (PKU) (2021-2030) ($MN)
  • Table 33 Global Metabolism Drugs Market Outlook, By Gaucher Disease (2021-2030) ($MN)
  • Table 34 Global Metabolism Drugs Market Outlook, By Fabry Disease (2021-2030) ($MN)
  • Table 35 Global Metabolism Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.